Lv1
86 积分 2024-06-04 加入
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
7个月前
已完结
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
7个月前
已完结
Potential Value of AURKA and CDK6 Amplification for the Response of Patients With Gastric Cancer to Neoadjuvant Chemotherapy
8个月前
已完结
Comprehensive molecular analysis identifies RET alterations association with response of ICIs in multi-immunotherapy cohorts
11个月前
已完结
皖公网安备34019202002308
